Effect of anemia on prognosis of patients with advanced solid tumors receiving immunotherapy
Objective To explore the effect of anemia on prognosis of patients with advanced solid tumors receiving immunotherapy.Methods Basic data,hemoglobin(Hb)concentration before immunotherapy and survival were collected in 59 patients with advanced solid tumors,and the influencing factors of progression-free survival(PFS)were analyzed.Results Univariate analysis showed that performance status(PS)score and anemia were the influencing factors of PFS in patients with advanced solid tumors receiving immunotherapy(P<0.05).Multivariate analysis showed that PS score≥2 points and moderate anemia were independent risk factors for PFS in patients with advanced solid tumors receiving immunotherapy(P<0.05).The median PFS of 59 patients was 6.7 months,and the median PFS of patients with normal Hb level and mild anemia were 6.9 months and 6.7 months,respectively,which were significantly longer than 1.9 months of patients with moderate anemia(P<0.05).There was no significant difference in median PFS between patients with mild anemia and patients with normal Hb levels(P>0.05).Conclusion In patients with advanced solid tumors receiving immunotherapy,the median PFS of patients with anemia is shorter than that of patients without anemia,which is one of the risk factors affecting the prognosis of patients with advanced solid tumors receiving immunotherapy.
万方数据
维普
